natgillin/translations-raw huggingface dataset:
That treatment with Peyona must be provided in a neonatal intensive care unit and initiated and supervised by a physician experienced in neonatal intensive care
Zdravljenje z zdravilom Peyona je treba nuditi v enoti za intenzivno nego novorojenčkov, začeti in nadzorovati pa ga mora zdravnik, izkušen v intenzivni negi novorojenčkov.
That treatment with Volibris causes peripheral oedema and fluid retention
Da zdravljenje z zdravilom Volibris povzroča periferne edeme in zastajanje tekočine
That treatment with Volibris often causes a decrease in haemoglobin and haematocrit
Da zdravljenje z zdravilom Volibris pogosto povzroči znižanje hemoglobina in hematokrita
That TYSABRI therapy is to be initiated and continuously supervised by specialised physicians experienced in the diagnosis and treatment of neurological conditions, in centres with timely access to MRI.
Zdravljenje z zdravilom TYSABRI uvede in neprestano nadzoruje zdravnik specialist z izkušnjami v diagnosticiranju in zdravljenju nevroloških bolezni, v centrih s hitrim dostopom do MRS.
That use of Atripla should be avoided with concomitant or recent use of nephrotoxic medicinal products.
Da se je treba uporabi zdravila Atripla izogibati pri sočasni ali nedavni uporabi nefrotoksičnih zdravil.
That vandetanib may cause Posterior reversible encephalopathy syndrome (PRES) also known as Reversible posterior leukoencephalopathy syndrome (RPLS)
Da lahko vandetanib povzroči sindrom posteriorne reverzibilne encefalopatije (PRES), znan tudi kot sindrom reverzibilne posteriorne levkoencefalopatije (RPLS).
That Vibativ has a risk of nephrotoxicity including increased risk of mortality in patients with pre existing acute renal failure and is therefore contraindicated in patients with pre-existing acute renal failure and in patients with creatinine clearance < 30ml/min, including patients undergoing haemodialysis.
Pri zdravilu Vibativ obstaja tveganje za nefrotoksičnost, vključno s povečanim tveganjem smrtnosti pri bolnikih s predobstoječo akutno ledvično odpovedjo in je zato kontraindicirano pri bolnikih s predhodno akutno ledvično odpovedjo ter pri bolnikih z očistkom kreatinina <
That Volibris is potentially hepatotoxic
Da je zdravilo Volibris lahko hepatotoksično
That Volibris is teratogenic
Da je zdravilo Volibris teratogeno
That Volibris may cause serious birth defects in unborn babies conceived before, during, or within a month after stopping treatment.
da lahko zdravilo Volibris povzroči resne okvare ploda, če ženska zanosi pred, med ali v enem mesecu po prekinitvi zdravljenja;
That Volibris should be initiated with caution in patients with severe renal impairment.
Da je treba zdravilo Volibris pri bolnikih s hudo okvaro ledvic uvesti previdno.
That women of child bearing potential must use effective contraception
da morajo ženske v rodni dobi jemati učinkovito kontracepcijo
That women of childbearing potential must use reliable contraception;
da morajo ženske v rodni dobi uporabljati učinkovito kontracepcijo;
That women receiving Volibris should be advised of the risk of foetal harm.
Ženske, ki prejemajo zdravilo Volibris, je treba seznaniti s tveganjem za okvaro ploda.
That XALKORI may cause vision disorders, including Grade 4 visual field defect with vision loss.
Zdravilo XALKORI lahko povzroči motnje vida, vključno z izpadom vidnega polja stopnje 4 z izgubo vida.
Thaw Imlygic vial(s) at room temperature.
Na sobni temperaturi odtajajte eno ali več vial zdravila Imlygic.
Thaw rapidly the contents of the ampoules by agitation in water at 25°C-30°C. Proceed immediately to next step.
Vsebino ampule odtajajte hitro s pretresanjem v vodi pri 25 °C do 30 °C. Nato takoj nadaljujte z naslednjim korakom.
Thaw rapidly the contents of the ampoules by gentle agitation in water at 27–39 °C.
Hitro odtajajte vsebino ampul z nežnim mešanjem v vodi pri 27-39°C.
Thaw the contents of the ampoules rapidly by agitation in water at 25°C-30°C. Proceed immediately to next step.
Vsebino ampule odtajajte hitro s pretresanjem v vodi pri 25 °C do 30 °C. Nato takoj nadaljujte z naslednjim korakom.
Thaw the unopened bottle rapidly between 33-35°C for a time period of 10 minutes in a thermostatic water bath.
Zaprto stekleničko hitro odtajajte v termostatični vodni kopeli pri temperaturi 33–35 °C v časovnem obdobju 10 minut.
Thaw unopened bottles rapidly between 33-35°C for a time period of 10 minutes in a thermostatic water bath.
Zaprte stekleničke hitro odtajajte v termostatični vodni kopeli pri temperaturi 33–35 °C v časovnem obdobju 10 minut.
Thawed Imlygic is stable when stored at temperatures of 2°C up to 25°C protected from light in its original vial, in a syringe, or in the original vial followed by a syringe.
Odtajano zdravilo Imlygic je stabilno, kadar ga shranjujete pri temperaturi od 2°C do 25°C, zaščiteno pred svetlobo v originalni viali, v injekcijski brizgi, ali v originalni viali in nato v injekcijski brizgi.
Thawing
Odtaljevanje
Thawing Imlygic vials
Odtajanje vial zdravila Imlygic
Thawing:
Odtaljevanje:
The
Za
The %IDSN was 1.68% ± 1.22% in the 3 hour injection-to-surgery group and 1.81% ± 2.19% in the Lymphoseek 16 hour injection-to-surgery group.
Vrednost %IDSN v skupini s 3 urami med injiciranjem in kirurškim posegom je bila 1,68 % ± 1,22 %, v skupini s 16 urami med injiciranjem zdravila Lymphoseek in kirurškim posegom pa 1,81 % ± 2,19 %.
The 0 must lines up with the dose pointer.
Število 0 mora biti poravnano s kazalnikom odmerka.
The 0.5 mg and 2 mg tablets also contain yellow iron oxide and brown iron oxide.
Tableti po 0,5 mg in 2 mg vsebujeta tudi rumeni železov oksid in rjavi železov oksid.
The 0.5 mg tablet is not fully bioequivalent to the 1 mg, 2 mg and 5 mg tablets when comparing Cmax.
0,5-miligramska tableta pri primerjavi Cmax ni popolnoma biološko enakovredna tabletam po 1 mg, mg in 5 mg.
The 0.5 mg tablets are white, round and biconvex with bevelled edges.
0,5-mg tablete so bele, okrogle in izbočene, s posnetim robom.
The 1 mg blister is printed with green ink and has one raised dot on the protruding end of each blister.
1 mg pretisni omot ima oznako, natisnjeno z zeleno barvo, in po eno izbočeno točko na vrhu vsakega posamičnega pretisnega omota.
The 1 mg prolonged-release tablets are round and white, hard tablets, debossed with 1MG on one side and 503 on the other side.
1 mg tablete s podaljšanim sproščanjem so okrogle in bele, trde tablete, z vtisnjenim napisom 1MG na eni strani in 503 na drugi strani.
The 1 ml measuring syringe has a kg-body weight scale for cats (0.5 to 10 kg).
1 ml brizgalka ima merilno skalo z oznakami telesne mase v kilogramih in sicer od 0,5 kg do 10 kg.
The 1 ml oral syringe is graduated from 0.05 to 1 ml in steps of 0.05 ml.
ml brizga ima označbe od 0,05 do 1 ml v korakih po 0,05 ml.
The 1 pre- filled pen pack comes with 2 alcohol pads (1 spare).
Pakiranje z 1 napolnjenim injekcijskim peresnikom ima priložena 2 alkoholna zloženca (1 dodatni).
The 1 pre- filled pen pack comes with 2 alcohol pads (1 spare).
Pakiranje z 1 napolnjenim injekcijskim peresnikom ima priložena 2 alkoholna zloženca (1 odvečni).
The 1 year and 2 year survival rates for patients on pemetrexed were 58 % and 32 % respectively, compared to 45 % and 21 % for patients on placebo.
Stopnji preživetja pri 1 in pri 2 letih pri bolnikih, ki so prejemali pemetreksed, sta bili 58 % in 32 %, v primerjavi s 45 % in 21 % pri bolnikih, ki so prejemali placebo.
The 1,000 mg tablet has special score lines so that it can be easily divided into four equal parts.
1 000–miligramska tableta ima posebne zareze, ki omogočajo enostavno razdelitev na štiri enake dele.
The 1-, 2- and 3-year rates of overall survival for Empliciti in combination with lenalidomide and dexamethasone treatment were 91%, 73%, and 60% respectively, compared with 83%, 69%, and 53% respectively, for lenalidomide and dexamethasone treatment (See Figure 2).
Pri zdravljenju z zdravilom Empliciti v kombinaciji z lenalidomidom in deksametazonom je delež 1 letnega celokupnega preživetja znašal 91 %, delež 2 letnega celokupnega preživetja 73 %, delež 3 letnega celokupnega preživetja pa 60 %, v primerjavi z zdravljenjem z lenalidomidom in deksametazonom, kjer je delež 1 letnega celokupnega preživetja znašal 83 %, delež 2 letnega celokupnega preživetja 69 %, delež 3 letnega celokupnega preživetja pa 53 % (glejte sliko 2).
The 1-year (74%) and 2-year (51%) OS estimates for the combination arm were greater than those for dabrafenib monotherapy (68% and 42% respectively).
Ocenjene stopnje preživetja (OS) po 1 letu (74 %) in po 2 letih (51 %) v skupini s kombiniranim zdravljenjem so bile večje kot v skupini z uporabo dabrafeniba v monoterapiji (68 % v primerjavi z 42 %).
The 1-year (75 %) and 2-year (48 %) OS estimates for the Cotellic plus vemurafenib arm were greater than those for placebo plus vemurafenib arm (64 % and 38 % respectively).
Ocenjeno celokupno preživetje po 1 letu (75 %) in 2 letih (48 %) je bilo za za skupino, ki je prejemala zdravilo Cotellic in vemurafenib, večje kot za skupino, ki je prejemala placebo in vemurafenib (64 % po 1 letu in 38 % po 2 letih).
The 1-year event free rate was 52.6% (± 5.72%) for the Pom + LD-Dex arm and 28.4% (± 7.51%) for the HD-Dex arm.
Enoletna stopnja brez dogodkov je bila 52,6 % (± 5,72 %) za skupino POM + NO-deks in 28,4 % (± 7,51 %) za skupino VO- deks.
The 1.5 mg tablets are orange-brown and printed with “PAL 1.5”, the 3 mg tablets are white and printed with “PAL 3”, the 6 mg tablets are beige and printed with “PAL 6”, the 9 mg tablets are pink and printed with “PAL 9”, and the 12 mg tablets are dark yellow and printed with “PAL 12”.
1,5 mg tablete so oranžno-rjave z oznako “PAL 1.5”, 3 mg tablete so bele z oznako “PAL 3”, 6 mg tablete so rjavkaste z oznako “PAL 6”, 9 mg tablete so roza z oznako “PAL 9” in 12 mg tablete so temno rumene z oznako “PAL 12”.
The 1.6 g powder for oral suspension should be dispersed in 40 ml of water per sachet.
1,6 g praška za peroralno suspenzijo raztopite v 40 ml vode na vrečko.
The 10 mg capsule is a yellow body and yellowish red cap, approximately 14.3 mm in length, marked in black ink with “Є” on the cap, and “LENV 10 mg” on the body.
10-miligramska kapsula ima rumeno telo in rumenkastordeč pokrovček, dolžine približno 14,3 mm, na njej je s črnim črnilom izpisana oznaka »Є« na pokrovčku kapsule in »LENV 10 mg« na telesu kapsule.
The 10 mg film-coated tablets are pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings ‘1 0’ on one side and ‘M M’ on the other side.
10 mg filmsko obložene tablete so bledo rumene do rumene, ovalne, z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in vtisnjeno besedo "M M" na drugi strani.
The 10 mg film-coated tablets are white to off-white, capsule shaped (12.5 x 5.6 mm), biconvex tablets with a break score on one side and embossed with “10” on the other side.
10 mg filmsko obložene tablete so bele do belkaste, kapsulaste (12,5 x 5,6 mm), bikonveksne tablete z razdelilno zarezo na eni strani in napisom »10« na drugi.
The 10 mg film-coated tablets are white to off-white, capsule shaped (12.5 x 5.6 mm), biconvex tablets with a break score on one side and embossed with “10” on the other side.
10 mg filmsko obložene tablete so bele do belkaste, kapsulaste (12,5 x 5,6 mm), bikonveksne tablete z razdelilno zarezo na eni strani in natisom »10« na drugi.
The 10 mg strength of the medicinal product contains 0.4 mg of sodium per vial of powder.
Ena viala zdravila z jakostjo 10 mg vsebuje 0,4 mg natrija.
The 10 mg vial is for children prescribed a dose of 10 mg or less.
10-mg viala je namenjena za uporabo pri otrocih s predpisanim odmerkom 10 mg ali manj.
The 10 mg vial strength may be more appropriate for administration to children with JIA below the weight of 25 kg.
Pri otrocih z juvenilnim idiopatskim artritisom, ki imajo telesno maso, manjšo od 25 kg, bo morda primernejša uporaba 10 mg viale.
The 100 mg chewable tablet is orange-banana flavoured and can be split into equal halves if necessary; however, breaking the tablets should be avoided.
100 mg žvečljiva tableta ima okus po pomaranči in banani ter se jo lahko deli na enaki polovici, če je to potrebno, vendar pa se je lomljenju tablet treba izogibati.
The 100 mg vial contains an overfill to allow the withdrawal of 100 mg when reconstituted if following the directions described below.
100 ml viala vsebuje presežek za zagotovitev odvzema 100 mg pri rekonstituciji, če se sledi spodnjim navodilom.
The 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection bag, needle and syringe should be unpacked (not provided in the pack).
Pripravite vrečko s 100 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje ter iglo in brizgo (niso priložene).
The 100 units/mL pre-filled pen delivers 1 - 80 units in steps of 1 unit.
Napolnjeni injekcijski peresnik 100 enot/ml omogoča aplikacijo od 1 do 80 enot v korakih po 1 enoto.
The 100 units/ml strength is approved in vials, cartridges, prefilled OptiSet pens and prefilled SoloStar pens.
Jakost 100 enot/ml je na voljo v vialah, vložkih, napolnjenih peresnikih OptiSet in napolnjenih peresnikih SoloStar.
The 100 units/ml strength is used to treat diabetes in patients aged two years or older.
Jakost 100 enot/ml se uporablja za zdravljenje sladkorne bolezni pri bolnikih, starejših od dveh let.
The 100 units/ml strength should be given in the evening in patients aged less than 18 years.
Bolnikom, mlajšim od 18 let, je treba zdravilo v jakosti 100 enot/ml injicirati zvečer.
The 1000 mg film-coated tablets are white, oblong and scored on both sides.
1000 mg filmsko obložene tablete so bele, podolgovate, z zarezo na obeh straneh.
The 12-month OS estimate was 72% for combination therapy and 65% for vemurafenib.
Ocenjeni stopnji celokupnega preživetja po 12 mesecih sta bili 72 % pri uporabi kombiniranega zdravljenja in 65 % pri uporabi vemurafeniba.
The 12.5 mg dose in the LIR subgroup also demonstrated shorter time to first post-dose SBM as compared to placebo in Kodiac 4 (p=0.002) and Kodiac 5 (p<0.001).
Tudi z odmerkom 12,5 mg je bil čas do prvega spontanega iztrebljanja po odmerku v podskupini LIR krajši kot s placebom tako v Kodiac 4 (p = 0,002) kot v Kodiac 5 (p < 0,001).
The 12.5 mg dose in the LIR subgroup also resulted in greater improvement in total PAC SYM at week 12 compared with placebo in both studies (p= 0.020 and p=0.001 respectively).
Tudi odmerek 12,5 mg je v podskupini LIR po 12 tednih v obeh študijah prinesel večje izboljšanje celotne PAC SYM kot placebo (Kodiac 4 p = 0,020 in Kodiac 5 p = 0,001).
The 120 mg film-coated tablets are marked on one side with ‘120’.
120 mg filmsko obložene tablete imajo na eni strani vtisnjeno oznako ‘120’.
The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
125 mg trda kapsula je neprozorna; telo je bele barve, pokrovček je rožnate barve; na sredini ima odtisnjeni črni oznaki "462" in "125 mg".
The 125 mg hard capsule is opaque with a white body and pink cap with “462” and “125 mg” printed radially in black ink on the body.
125 mg trda kapsula je neprozorna; telo je bele barve, pokrovček rožnate barve; na sredini ima odtisnjeni črni oznaki "462" in "125 mg".
The 125 micrograms grey pens are provided in a pack containing either two or six pre-filled pens.
Pakiranje s sivimi injekcijskimi peresniki s 125 mikrogrami vsebuje dva ali šest napolnjenih injekcijskih peresnikov.
The 125 micrograms grey syringes are provided in a pack containing either two or six pre-filled syringes.
Pakiranje s sivimi injekcijskimi brizgami s 125 mikrogrami vsebuje dve ali šest napolnjenih injekcijskih brizg.
The 13- week study was performed to confirm that the change in route of administration and the use of the novel excipient recombinant human hyaluronidase (rHuPH20) did not have an effect on the Herceptin safety characteristics.
Študija, ki je trajala 13 tednov, pa je bila opravljena, da bi potrdili, da sprememba poti aplikacije in uporaba nove pomožne snovi humane hialuronidaze (rHuPH20) ni imela vpliva na varnostne lastnosti zdravila Herceptin.
The 14-day ”lead-in” period has been shown to lower the risk of skin rash.
Pokazalo se je, da 14-dnevno ”uvajalno” obdobje zmanjša tveganje kožnega izpuščaja.
The 14-day”lead-in” period has been shown to lower the risk of skin rash.
Pokazalo se je, da 14-dnevno ”uvajalno” obdobje zmanjša tveganje za pojav kožnega izpuščaja.
The 140 mg once daily regimen showed a comparable efficacy profile to the 70 mg twice daily regimen but a more favourable safety profile.
Profil učinkovitosti režima odmerjanja 140 mg enkrat na dan je bil primerljiv s profilom učinkovitosti odmerjanja 70 mg dvakrat na dan, vendar pa je bil profil varnosti pri režimu odmerjanja 140 mg enkrat na dan ugodnejši.
The 144-week, double-blind, active controlled phase of study GS-99-903 evaluated the efficacy and safety of tenofovir disoproxil 245 mg (as fumarate) versus stavudine when used in combination with lamivudine and efavirenz in HIV-1 infected adult patients naïve to antiretroviral therapy.
144 tednov trajajoča, dvojno slepa, aktivno kontrolirana faza študije GS-99-903 je ocenjevala učinkovitost in varnost 245 mg dizoproksiltenofovirata (v obliki dizoproksiltenofovirijevega fumarata) napram stavudinu pri uporabi v kombinaciji z lamivudinom in efavirenzom pri odraslih bolnikih okuženih s HIV-1, še nezdravljenih s protiretrovirusnimi zdravili.
The 15 mg film-coated tablets are orange to grey-orange, oval-oblong film-coated tablets with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "15" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
The 15 mg film-coated tablets are orange to grey-orange, oval-oblong film-coated tablets with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalno podolgovate, z vtisnjeno številko "15" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
The 15 mg film-coated tablets are white to off-white, capsule shaped (14.0 x 6.0 mm), biconvex tablets plain on one side and embossed with “15” on the other side.
15 mg filmsko obložene tablete so bele do belkaste, kapsulaste (14,0 x 6,0 mm), bikonveksne tablete, ravne na eni strani in z napisom »15« na drugi.
The 15 mg tablets furthermore contain iron oxide yellow, red and black (E172).
15 mg tablete vsebujejo tudi rumeni, rdeči in črni železov oksid (E172).
The 150 mg tablet is bioequivalent and dose proportional to the 300 mg tablet with respect to AUC∞, Cmax, and tmax.
Tableta sily 150 mg je bioekvivalentná a dávkovo proporčná 300 mg tablete pokiaľ ide o AUC∞, Cmax, a tmax.
The 154 children who achieved an ACR Ped 30 response at week 16 entered Part 2 of the study, the randomised withdrawal phase, and received Simponi 30 mg/m2 (maximum 50 mg) + MTX or placebo + MTX every 4 weeks.
154 otrok, ki je v 16. tednu doseglo odziv ACR Ped 30, so vključili v drugi del študije, in sicer v randomizirano fazo odtegnitve zdravila, v kateri so vsake 4 tedne prejeli 30 mg/m2 (največ 50 mg) zdravila Simponi in metotreksat ali placebo in metotreksat.
The 160 g sachet is sufficient to treat a total of 20,000 kg of pigs (e.g.
160-gramska vrečka zadošča za zdravljenje prašičev s skupno težo 20000 kg (npr.
The 160 mg/20 mg tablets have the letters ‘S’ and ‘T’ on one side and come in blisters containing 3 tablets.
Tablete 160 mg/20 mg imajo na eni strani črki „S“ in „T“ in so na voljo v pretisnih omotih s 3 tabletami.
The 165 mg hard capsule is opaque with a light blue cap and a white body with “466” and “165 mg” printed radially in black ink on one side of the body and the Merck logo on the other side.
165 mg trda kapsula je neprozorna, s pokrovčkom svetlo modre barve in telesom bele barve; na eni strani sta na telo radialno s črnim črnilom natisnjeni oznaki "466" in "165 mg", na drugi strani pa je Merckov logotip.
The 18 week STRIDE-2 trial, conducted in 246 patients, included 4 treatment arms: placebo once daily, Thelin 50 mg once daily, Thelin 100 mg once daily, and open-label bosentan twice daily (efficacy-rater blinded, administered according to the approved package insert).
V preskušanju STRIDE-2, kjer je bilo vključenih 246 bolnikov in je trajalo 18 tednov, so primerjali 4 skupine bolnikov: bolnike, ki so jemali placebo enkrat dnevno; bolnike, ki so jemali zdravilo Thelin 50 mg enkrat dnevno; bolnike, ki so jemali zdravilo Thelin
The 1st click indicates the injection has started.
1. klik pomeni, da se je injiciranje začelo.
The 2 active ingredients in the veterinary medicine act by contact on the parasites.
Obe aktivni učinkovini v zdravilu za uporabo v veterinarski medicini delujeta preko kontakta s parazitom.
The 2 mg prolonged-release tablets are oval and white, hard tablets, debossed with 2MG on one side and 503 on the other side.
2 mg tablete s podaljšanim sproščanjem so ovalne in bele, trde tablete, z vtisnjenim napisom 2MG na eni strani in 503 na drugi strani.
The 2 treatment groups were comparable with respect to demographic and baseline disease characteristics.
Obe skupini zdravljenja sta bili glede na demografske značilnosti in značilnosti izhodiščne bolezni med seboj primerljivi.
The 2-week carton contains 28 blister strips (of 10 capsules each) and two inhaler devices.
Škatla za 2-tedensko zdravljenje vsebuje 28 pretisnih trakov (po 10 kapsul) in dva inhalatorja.
The 2-year estimates of EFS were 66 % among subjects receiving dinutuximab immunotherapy plus isotretinoin as compared with 48 % in subjects receiving isotretinoin alone (log-rank test p = 0.033) although this difference did not reach formal statistical significance according to the pre-specified plan for interim analyses.
Dvoletna ocena EFS je bila 66 % pri bolnikih, zdravljenih z imunoterapijo z dinutuksimabom skupaj z izotretinoinom, v primerjavi z 48 % pri bolnikih, zdravljenih samo z izotretinoinom (log-rank test p = 0,033), čeprav razlika glede na v naprej določen načrt za vmesne analize ni bila statistično značilna.
The 2-year OS rate was 61.9% (95%CI, 51.1-72.7%)].
Stopnja celokupnega preživetja po 2 letih je bila 61,9 % (95-odstotni IZ 51,1–72,7 %)].
The 2.3 ml of solvent should be withdrawn from the solvent vial attached directly to a 3-ml syringe and then injected into the powder vial for reconstitution with 27-gauge, ½-inch needle (to obtain a final reconstitution volume of 2.75 ml).
2,3 ml vehikla povlecite iz viale z vehiklom, ki je neposredno priložena trimililitrski brizgi, in jo nato s polpalčno iglo kalibra 27 injicirajte v vialo s praškom za rekonstitucijo (da boste dobili končni rekonstituirani volumen 2,75 ml).
The 2.4 g powder for oral suspension should be dispersed in 60 ml of water per sachet.
2,4 g praška za peroralno suspenzijo raztopite v 60 ml vode na vrečko.
The 2.5 mg strength is also used to treat adults with unstable angina (a type of chest pain that changes in severity due to reduced blood flow to the heart) or who are having a myocardial infarction (heart attack) with or without ‘ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG).
2,5-miligramski odmerek se uporablja tudi za zdravljenje odraslih ljudi z nestabilno angino pektoris (vrsto bolečine v prsih, katere jakost se spreminja zaradi zmanjšanega dotoka krvi v srce) ali miokardnim infarktom (srčnim napadom) z „dvigom spojnice ST“ (nenormalnim izpisom na elektrokardiogramu ali EKG-ju) ali brez njega.